In animal models, E1 - deleted
human adenoviral recombinants of the serotype 5 (AdHu5) have shown high efficacy as vaccine carriers.
The closest
human adenoviral relatives were the species D adenoviruses, which share 54.3 % to 55.1 % identity to TMAdV, with human adenoviruses of other species slightly less similar (51.1 % — 54.6 %).
However, the high sequence divergence in the fiber protein (Table 2), as well as the absence of fiber motifs conserved among adenoviruses that bind CAR [36], [37](coxsackievirus - adenovirus receptor) or CD46 [38], [39], [40](data not shown), suggest that neither of these two
human adenoviral receptors may be the attachment receptor for TMAdV.
Not exact matches
The high degree of sequence relatedness within members of each species suggests that at least some
adenoviral strains may be capable of infecting both nonhuman primates and
humans.
In the current work we used
adenoviral - type 5 (dE1 / E3)(Cytomegalovirus promoter) with
human ABCA10 transgene (Ad - h - ABCA10) purchased from Vector Labs ® in order to investigate whether gene therapy can be used as a pre-treatment to enhance the efficiency of inhaled cisplatin.
Lack of preexisting virus - neutralizing antibodies in the
human population suggests that these novel
adenoviral recombinants may provide improved vaccine carriers for use in
humans.
Adenoviral vectors can be produced by
human embryonic kidney (HEK293) and
human embryonic retinal (PER.C6) cell lines (31), both of which also can be used for lentiviral vector production.
Both vectors are
human serotype 5, replication - defective, first generation
adenoviral vectors deleted in E1a and E3 viral encoding regions.